2023 GEIS Guidelines for gastrointestinal stromal tumors.

49 Mutations within PDGFRA showed a trend toward a better prognosis.

also in 53,322 other papers

59 Despite the overt impact of imatinib on RFS, there were no differences in OS or in imatinib failure-free survival (IFFS) – an innovative end point capturing the time to the development of secondary resistance to imatinib in the metastatic setting – although there was a nonsignificant trend toward IFFS improvement in high-risk patients.

also in 5,406 other papers